Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,590 followers.

Our cases of more than 6 months of Alectinib as an adjuvant that got PCR： Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports http

30 Nov 2023

Reply Repost Favourite

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangem… https://t.co/nDcZCiVAjo https://t.co/owLRUcq0RW

06 Jul 2023

Reply Repost Favourite

New research: Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports: Objective Despite the promising efficacy and… #oncology https:

29 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.